Advertisement

Topics

Euronext N.V Company Profile

13:31 EST 23rd November 2017 | BioPortfolio

Euronext N.V., a holding company incorporated under Dutch law that operates through local subsidiaries, was formed on 22 September 2000 when the exchanges of Amsterdam, Brussels and Paris merged. The Euronext group expanded at the beginning of 2002 with the acquisition of LIFFE (London International Financial Futures and Options Exchange) and the merger with the Portuguese exchange BVLP (Bolsa de Valores de Lisboa e Porto). Today, Euronext is Europe’s leading cross-border exchange, integrating trading and clearing operations on regulated and non-regulated markets for cash products and derivatives. Euronext was formed in 2000 in response to the globalisation of capital markets and to create a pan-European exchange offering its participants increased liquidity and lower transaction costs.

Location

Cannon Bridge House1 Cousin Lane
London
London
EC4R 3XX
United Kingdom

Contact

Phone: 44 20 7623 0444
Email: infolist@euronext.com


News Articles [114 Associated News Articles listed on BioPortfolio]

Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - November 16, 2017

Article 223-16 of general regulation of French Autorité des Marchés Financiers Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market.....

Ablynx: SUSPENSION OF TRADING IN ABLYNX SHARES ON EURONEXT BRUSSELS

REGULATED INFORMATION GHENT, Belgium, 25 October 2017 (1 pm CEST) - Trading in the shares of Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY] was suspended at the request of the Company on 25 Octob...

NOXXON Pharma Announces Prospectus Publication and Share Transfer to the Public Offering Compartment of the Euronext Growth Market

COMPARTMENT TRANSFER TRIGGERS FURTHER FINANCING AND REDUCTION OF DEBT Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (EuroNext Growth Paris: ALNOX), a biotechnology company, which focuses on im...

Erytech Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

Regulatory News: NOT FOR DISTRIBUTION IN AUSTRALIA, CANADA OR JAPAN ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP) ("ERYTECH" or "the Company") announces trading resumption of its ...

French Biotech Launches €30M IPO to be the First to Treat Rare Disease in Children

Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys, to the market. Advicenne, based in Nîmes, France, has offici...

French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s

Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexu...

Inventiva raises €48m in Euronext IPO

SUSPENSION OF TRADING IN ABLYNX SHARES ON EURONEXT BRUSSELS

REGULATED INFORMATION GHENT, Belgium, 25 October 2017 (1 pm CEST) - Trading in the shares of Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY] was suspended at the request of the Company on ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [55 Associated Companies listed on BioPortfolio]

Euronext N.V

Euronext N.V., a holding company incorporated under Dutch law that operates through local subsidiaries, was formed on 22 September 2000 when the exchanges of Amsterdam, Brussels and Paris merged. The ...

NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trad...

Nutreco Holding N.V.

Nutreco Holding N.V. is an international company in the animal nutrition and fish feed markets, where it seeks to create added value through its knowledge of the food chains. The company has a selecte...

Gemalto

Gemalto (Euronext NL 0000400653 GTO) is the world leader in digital security with 2009 annual revenues of €1.65 billion, and over 10,000 employees operating out of 75 offices...

Galapagos nv

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs...

More Information about "Euronext N.V" on BioPortfolio

We have published hundreds of Euronext N.V news stories on BioPortfolio along with dozens of Euronext N.V Clinical Trials and PubMed Articles about Euronext N.V for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Euronext N.V Companies in our database. You can also find out about relevant Euronext N.V Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record